LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Avatud

SektorTervishoid

0.49 -40.96

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.49

Max

0.83

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M -8.1M
Müük	-5.9M 35M
Aktsiakasum	-0.04
Kasumimarginaal	-23.367
Töötajad	128
EBITDA	-4M -4.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+321.69% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-68M 163M
Eelmine avamishind	41.45
Eelmine sulgemishind	0.49

Uudiste sentiment

By Acuity

32%

68%

74 / 344 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. juuni 2026, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. juuni 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. juuni 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. juuni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. juuni 2026, 21:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. juuni 2026, 20:46 UTC

Omandamised, ülevõtmised, äriostud

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. juuni 2026, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares $11 Special Div

1. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. juuni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. juuni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. juuni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. juuni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. juuni 2026, 18:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. juuni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. juuni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. juuni 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. juuni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. juuni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 17:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

321.69% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 321.69%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

74 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.